Objective. We aimed to investigate gender differences in disease manifestations, patient-reported outcomes, comorbidities and treatment effectiveness among patients with PsA treated with their first TNFa inhibitor (TNFI).
Introduction
The introduction of biologic DMARDs (bDMARDs), such as TNFa inhibitors (TNFIs), has improved the prognosis for patients with PsA over the past decades, and clinical trials have established strong evidence for high efficacy of these drugs [1] . However, in routine care, <50% of patients obtain sustained response to TNFI treatments [2] . This emphasizes a need for patient stratification and personalized treatment strategies, especially as the repertoire of disease-modifying drugs with different modes of action is rapidly increasing [3] . Several factors have been proposed to influence TNFI effectiveness in PsA, albeit the evidence for their impact is still limited [4] .
A negative effect of female gender on biologic treatment outcomes in PsA has been suggested, although conflicting results exist, and few authors have aimed at looking into the possible underlying mechanisms [515] . Gender disparities in the pathophysiology and clinical expression of PsA, and in the pharmacokinetics and dynamics of the drugs, as well as in side effect profiles and compliance to medication, might potentially affect treatment outcomes [1619] .
The aim of the current study was to investigate gender differences in baseline characteristics and treatment outcomes among Danish PsA patients who started their first TNFI course between 2000 and 2015. The Danish nationwide DANBIO register includes >15 years of follow-up of PsA patients treated in routine care. Extensive data on demography, disease activity, patient-reported outcomes and lifestyle are collected prospectively by an online system. By register linkage to national health care registers, information on comorbidities was obtained, giving us a unique opportunity to study gender effects on TNFI effectiveness while accounting for several potential confounders [20, 21] .
Methods
The study was designed as an observational, nationwide, cohort study using prospectively collected data on patients who were diagnosed with PsA according to their treating rheumatologist. A pre-specified protocol, elaborated with input from a patient research partner with PsA, was uploaded at www.parkerinst.dk. The study adheres to the The Strengthening the Reporting of Observational Studies in Epidemiology statement [22] . The Danish Data Protection Agency approved the study (j.nr.: 2012-58-0004). Approval from the ethics committee was not required.
The DANBIO register and the Danish National Patient Register (DNPR) were used as data sources and crosslinked using patients' unique civil registration number. All bDMARD-naïve patients (518 years old) who initiated TNFI for PsA between 1 January 2000 and 26 January 2015 were eligible. Patients were excluded if they participated in clinical trials, had erroneous baseline information, were treated with non-TNFIs or were not followed in DANBIO from start of TNFI treatment.
The nationwide DANBIO register covers >90% of Danish adults treated with bDMARDs in routine rheumatology care. Patients are registered at treatment initiation and followed prospectively at least bi-annually. Parameters included in DANBIO have been described previously [23] . For the present study we retrieved data on demographics, anti-rheumatic treatments, disease activity, patient-reported outcomes, smoking and BMI. Data on dactylitis, enthesitis and psoriasis severity is not systematically recorded in DANBIO.
The DNPR is a comprehensive nationwide health care register that captures all somatic diagnoses from inpatients (since 1977) and outpatient (since 1995) secondary care units in Denmark. Since 1995, activities in psychiatric wards and emergency rooms have been included as well [21] . Diagnoses are coded according to the International Classification of Diseases version 10 (ICD-10) (since 1994).
The Charlson Comorbidity Index (CCI) [24] is a weighted index of 19 comorbidity categories. A severity score of 1, 2, 3 or 6 applies to each category, and the sum score equals the overall CCI, with higher scores reflecting worse comorbidity burden. A high accuracy of the DNPR diagnoses included in the CCI has been documented [25] . Using DNPR, we obtained complete information on comorbidities included in the CCI with the modification of excluding connective tissue diseases (weight = 1) due to risk of misclassification in this population. Patients were categorized according to this modified CCI (mCCI) index of 0, 1 or 52 (supplementary Table S1 , available at Rheumatology online). DNPR was also used to report frequencies of specific comorbidity categories including psoriasis, extra-articular manifestations (uveitis, urethritis and IBD), depression/anxiety and cardiovascular, metabolic, pulmonary and hepatic disorders. Supplementary Table S2 , available at Rheumatology online depicts diagnoses/ICD-10 codes of each category. We used a 10-year look-back window for retrieval of comorbidity diagnoses in DNPR, using TNFI start as index date [20] .
Outcome measures
Treatment duration was calculated as the number of days individual patients maintained treatment with their first TNFI. Start date was the first given dose, and stop date the first missed dose. All observations were censored on 25 May 2015. Patients without visits since 1 January 2015 were censored at the date of their last visit. Treatment interruptions of 43 months were allowed. Reasons for withdrawal are reported in DANBIO in pre-specified categories including: lack of effect, adverse events, disease remission, other reasons.
Response to treatment was based on disease activity and patient-reported outcomes recorded at baseline (defined as 30 days prior until 7 days after TNFI start date) and at 3 months (weeks 1017) and 6 months (weeks 1832) of follow-up. For HAQ-DI data a 12 months' (weeks 3965) follow-up was also assessed. In the case of several visits within a time window, the one closest to the time point of interest was chosen. If no registrations were available, data were coded as missing.
Primary outcome was achievement of a EULAR goodor-moderate response (EGOM) at 6 months. Secondary outcomes were EGOM at 3 months and EULAR good response and ACR 20/50/70 improvement at 3 and 6 months. These composite measures integrate information on 28 swollen (SJC) and tender (TJC) joint counts, CRP and clinician-and patient-reported variables as specified in supplementary Table S3 , available at Rheumatology online.
PsA-specific outcomes, such as the minimal disease activity (MDA) [26] , were inapplicable due to lack of information on enthesitis, 66/68 joint scores and skin activity in DANBIO. Instead, to further explore gender disparities in outcomes, we elaborated MDA-inspired criteria including: (i) minimal joint activity, defined as tender joint count 41 and swollen joint count 41 (out of 28 joints assessed) and (ii) patient-reported MDA (PR-MDA), defined as visual analogue scale (VAS) of pain 415 mm, VAS global 420 mm and HAQ Disability Index (HAQ-DI) 40.5. For the subgroup of patients with axial involvement defined as 51 BASMI measurement in DANBIO within the first 6 months of TNFI, we analysed the influence of gender on 6-month EGOM response and on TNFI persistence by logistic and Cox regression models adjusted for age and baseline BASDAI, as continuous measures.
Statistics
Data analyses were performed in SPSS Statistics, version 22 (IBM Corp., Armonk, NY, USA) and R version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). Baseline characteristics are described as number with corresponding percentages, means (S.D.) or medians with interquartile ranges (IQR) as appropriate. Comparisons were done by independent t test, MannWhitney U test or chi-square test, depending on data distribution. A P < 0.05 (two-sided) was considered statistically significant. Responses to treatment after 3 and 6 months were reported as observed percentages with 95% CI (per protocol analysis), as well as by LUNDEX-adjusted response rates with 95% CI. The LUNDEX rates take attrition bias into account and are calculated by multiplying response rates with drug persistence rates at the given time point [27] .
Changes in disease parameters (VAS fatigue/global/ pain/physician, HAQ-DI and CRP) from baseline to 3 and 6 months were calculated.
The influence of gender on treatment persistence was assessed by KaplanMeier plots and Cox proportional hazard models with treatment duration in years as underlying time scale, while the influence of gender on the likelihood of achieving 3-and 6-month responses was analysed by logistic regression. Two models were designed for Cox and logistic regression: model 1 adjusted for age (years), and model 2 adjusted for covariates selected a priori of which age (years), disease duration (years), swollen joint count (028), tender joint count (028) and VAS pain (0100) were continuous measures and CRP (510 vs <10 mg/l), current smoker (yes/no), obesity (BMI 5 30 kg/m 2 , yes/no), hospital-diagnosed depression or anxiety (yes/no), TNFI start year (200005 vs 200615) and mCCI (0/1/52) were categorical. We tested for possible interactions between gender and age, disease duration, obesity, mCCI and smoking, which was not found. Multicollinearity of VAS pain, SJC and TJC was tested and rejected as correlation coefficients were <0.5 and variance inflation factors were <2. The assumption of proportional hazards in the Cox analyses was confirmed by formal test of Schoenfeld residuals.
Sensitivity analyses
The following sensitivity analyses were performed: Concurrent MTX treatment was tested as confounder in the Cox regression (model 2).The influence of gender on TNFI withdrawal due to adverse events and lack of efficacy was studied separately (with covariates similar to Cox model 2), censoring other TNFI stop reasons. Gender differences in median TNFI persistence were reported for infliximab, etanercept and adalimumab, separately. A 'change in estimate' selection of covariates for the logistic regression (6-month EGOM response) was performed with stepwise and hierarchical inclusion of variables that changed the odds ratio (OR) for gender by 5 10% when tested in the basic model 1 (gender, age). Inclusion was stopped when the OR for gender changed by <10%. The advantage of this stepwise strategy is a reduced risk of overfitting while the drawback is the arbitrary confounding cut-off. We tested 21 variables as depicted in supplementary Table S4 , available at Rheumatology online. Risk of gender differences in missing baseline data was handled by imputation of co-variates included in the logistic regression model 2 (6-month EGOM response). We used the multiple imputations by chained equations procedure in the R package 'mice' to account for missing values, and subsequently pooled the logistic regression results using Rubin's Rules. We imputed 35 datasets based on 15 a priori selected covariates (supplementary Table S5 , available at Rheumatology online). To study gender differences in prognosis beyond 6 months, we compared the level of physical function by HAQ-DI scores in men and women after 1 year of treatment.
Results

Baseline data
From DANBIO we identified 1980 PsA patients of whom 1750 fulfilled the inclusion criteria and 935 (53%) of these were females. A patient population flowchart has previously been provided [20] . . In addition, a higher proportion of females than males were diagnosed with depression/anxiety and chronic pulmonary diseases (Table 1) . Infliximab was dosed by weight resulting in an average of 288 and 268 mg for men and women, respectively (P = 0.05), whereas no dose differences were observed for other TNFIs.
Response rates after 3 and 6 months in male and female patients Three-and 6-month response rates were significantly lower in women than in men across all response criteria, both by the per protocol analysis (Table 2 ) and after LUNDEX adjustment (Fig. 1) . For instance, the observed EGOM 6-month responses were 69%/81% in females/ males, corresponding to 51%/69% following LUNDEX adjustment. As seen in supplementary Table S6 , available at Rheumatology online, men experienced a greater improvement in both clinical and most patient-reported parameters from baseline to 3 and 6 months than women. In addition, males had a lower level of disability after 1 year of treatment with a median (IQR) HAQ-DI score of 0.25 (0.000.88) compared with 0.75 (0.251.25) in females (P < 0.001) (supplementary Table S7 , available at Rheumatology online).
The impact of gender on 3-and 6-month response outcomes
Gender differences in the odds for treatment response were observed for most criteria after 3 months, and were even more pronounced after 6 months ( Table 3 ). The greatest gender differences were seen for EULAR good, ACR50, PR-MDA and minimal joint activity outcomes and were less for EGOM and ACR20 (Table 3) . In sensitivity analysis using change in estimate selection of covariates, only smoking and obesity influenced the OR 5 10%, and of these, only obesity remained following forward selection, yielding a final model of gender, age and obesity with OR of 2.35 (95% CI: 1.37, 4.01) for 6-month EGOM response in men vs women. Multiple imputation of missing baseline data resulted only in a modest chance (OR = 2.76, 95% CI: 1.51, 5.04) for EGOM in males vs females.
In the subgroup of patients with axial manifestations (n = 422), males had an increased chance of EGOM 6-month response OR= 3.0 (95% CI: 1.3, 6.9), adjusted for baseline age and BASDAI score.
Drug persistence in male and female patients
The cohort was followed for a total of 4525 person-years and the median (IQR) follow-up time was 1.42 (0.52, 3.88) years. The TNFi persistence differed significantly between females and males (KaplanMeier analysis, Fig. 2 
FIG. 1 LUNDEX-adjusted response rates after 3 and 6 months in females and males
Percentage responders among females (black bar) and males (grey bar) after 3 and 6 months of follow-up. Comparison of response rates between genders by chi-square test result in P <0.01 for all shown outcomes. The whiskers represent 95% CI. EGOM: EULAR good or moderate response.
The impact of gender on TNFI persistence
Female gender was associated with an increased risk of TNFI withdrawal with a hazards ratio (HR) of 1.50 compared with males (Table 4) . Adjustment for concomitant methotrexate in the Cox regression analysis (model 2) did not influence the results [HR= 1.53 (1.23, 1.90) for females vs males]. Female gender was associated with TNFI withdrawal both due to lack of efficacy and due to adverse events (Table 4 ). In patients with axial manifestations, females also had an increased risk of TNFI withdrawal [HR = 1.99 (1.47, 2.68) vs men].
Discussion
Among 1750 Danish PsA patients initiating their first TNFI treatment course, male patients had a more favourable baseline profile including fewer comorbidities, and also a greater chance of achieving 3-and 6-month treatment response, as well as longer TNFI persistence.
Previous studies have explored predictors of TNFI outcomes by multivariable regression analyses (non-hypotheses approach) and thereby provided risk estimates for gender. The results of these studies diverge, possibly due to heterogeneity in design, statistical methods and choices of outcome measures [4, 6] . Some authors found no impact of gender on outcomes of biologic treatment [2730] , whereas most reported females to have poorer TNFI effectiveness [5, 715, 31] . Among the latter are two British cohort studies each including 596 TNFInaïve PsA patients, in which females had increased risk of TNFI discontinuation [13] and reduced 6-month EULAR good response [14] . Furthermore, an Italian cohort study of 420 TNFI-naïve PsA patients [15] and a Norwegian study of 1268 arthritis patients (172 with PsA) [31] reported increased risk of TNFI withdrawal in females (HR = 1.52.0), which was also concluded in a literature review from 2016 of nine PsA studies [8] . When studying the impact of gender among the subset with axial manifestations, we still found significantly poorer TNFI effectiveness in females. This is in line with previous studies on axial spondyloarthritis, including a post hoc analysis of pooled clinical trial data on 1283 AS patients, in which females had significant lower response rates and reduced odds for achieving a 12-week response to disease modifying drugs [OR =0.55 (95% CI: 0.40, 0.75) vs males] [32] . Furthermore, a meta-analysis by Maneiro et al.
[4] from 2015 concluded that male AS patients had better chances Results obtained by crude and adjusted logistic regression analysis. of treatment response based on 10 studies, and confirmatory results have been reported by recent studies [33, 34] .
The strength of observational cohort studies includes the opportunity to study real-life drug effectiveness and identify possible risk factors for outcomes. However, the risk of residual confounding must be kept in mind. By cross-linkage of nationwide registers, we retrieved data on multiple characteristics that have previously been associated both to TNFI outcomes in PsA, and to gender, including PsA disease activity, co-morbidities, mental health, extra-articular manifestations, patient-reported outcomes and lifestyle factors [20, 2729, 3537] . Despite adjustment for these potential confounders, male gender was still associated with better TNFI effectiveness, which could indicate a role of biological factors. Some previous studies of both PsA and axial PsA/SpA have reported poor prognostic factors such as dactylitis, enthesitis, poly-articular disease and progressive disability to be more common in females, which could imply a need for more intensive treatment regimes [16, 19, 3842] . In agreement with this, we observed females to have worse physical function than males after 1 year of treatment in the present study, and they also experienced less improvement in inflammatory makers such as CRP and SJC. A hypothesis of more enduring and treatment-resistant PsA disease in females could be supported by previous observations of enhanced female immunogenicity and pro-inflammatory capacity of female sex hormones, which may increase the susceptibility to develop anti-TNFI antibodies or interfere with TNFI drug metabolism, and thereby drug efficacy and tolerability [4345] . However, other studies have reported more severe psoriasis, worse radiographic spinal disease progression and a higher frequency of ocular involvement in men [18, 41, 4649] .
Although men and women had comparable baseline profiles regarding hospital-diagnosed psoriasis and extra-articular manifestations in our study, we had no prospective information on these disease variables, neither on dactylitis nor on enthesitis or arthritis of the feet. These limitations clearly attenuate our insight into gender differences in clinical phenotypes.
In our analyses, female gender was associated with poorer TNFI persistence due to both lack of effect and adverse events, whereas a study in patients with AS reported that female gender was only associated with increased withdrawal due to inefficacy [50] . Deeper insight into gender differences in reasons for withdrawal, including the specific types of adverse events leading to treatment termination, is warranted. This was not provided by our study as detailed and comprehensive information on TNFI stop reasons is a shortcoming in DANBIO.
Although we adjusted for patient-reported baseline variables, an impact of 'chronicity' must be kept in mind. Females were older, had more disability, worse fatigue and were more often diagnosed with depression/anxiety, which may all increase the susceptibility to chronic pain, negative disease perceptions and poorer coping strategies that per se counteract a treatment response. Accordingly, a Canadian study of 590 PsA patients found men to report less disability and greater healthrelated quality of life than women, in spite of more radiographic damage [18] . Although we observed a poorer achievement of the minimal patient-reported disease activity response in females, we are not able to determine the extent to which psychological vs physiological factors contribute to this finding. Finally, lower compliance to biologic therapies in females vs males has been documented in RA and Crohn's disease, and could also be an explanatory variable for the increased risk of TNFI failure among female patients with PsA.
To our knowledge this is the largest study to date examining gender differences in disease characteristics and TNFI effectiveness in a nationwide PsA population, and the first to include 15 years of prospectively collected data, as well as information on lifestyle factors and comorbidities. Comorbidity status was obtained from DNPR with high accuracy [25] , and independently of treatment and disease activity records in DANBIO, which reduces the risk of observer bias and enhances the external validity of our results. Additional strengths include adjustment for attrition bias by the LUNDEX tool and a variety of sensitivity analyses to test the robustness of our findings.
The study has several limitations of which the most important are the use of a 28 joint count, the lack of disease activity measures for extra-articular loci and the use of nonPsA-specific outcome criteria. The exploratory criteria (minimal joint activity and minimal patient-reported activity) are neither validated nor generally used in PsA, and should be interpreted with care. Further limitations include those inherent to register studies such as risk of selection bias, incorrect registrations and residual confounding. By including comorbidities registered 410 years prior to TNFI start, we acknowledge that some patients might have recovered despite the chronic or recurrent nature of most conditions. On the contrary, the comorbidity burden might have been underestimated, as diagnoses provided in primary care are not registered in DNPR. Further studies are needed to confirm our findings of gender discrepancies in TNFI effectiveness, and these should preferably include PsA-specific outcome measures, detailed information on TNFI stop reasons and measures of compliance, as well as laboratory results on, for example, drug neutralizing antibodies and TNFI drug concentrations.
Conclusion
In this prospective study of 1750 patients initiating TNFI for PsA, male gender was strongly associated with better TNFI effectiveness. The associations between gender and TNFI outcomes were independent of known risk factors and baseline imbalances, indicating a possible role of biological factors. Adjusted for age (years). b Adjusted for age (years), disease duration (years), CRP (<10/510 mg/l), tender joint count (028), swollen joint count (028), visual analogue scale pain (0100), current smoker (yes/no), obesity (yes/no), anxiety, depression (yes/no), TNFI start year (<2006/52006), modified Charlson Comorbidity Index (0/1/52). TNFI: TNFa inhibitor.
